The Circadian Modulators as Molecular Targets in Cancer-A Review

Anna Wolniakowska1, Joanna Roszak1, Zuzanna Sobańska1

  • 1Center for Alternative Methods for Toxicity Assessment, Nofer Institute of Occupational Medicine, Św. Teresy 8, 91-348 Łódź, Poland.

Insights

Circadian clock disruptions are linked to cancer. This review explores how targeting circadian clock modulators, like REV-ERBs and RORs, may offer new chemotherapy strategies for cancer treatment.

Area of Science:

  • Chronobiology
  • Oncology
  • Molecular Biology

Background:

  • Growing research links circadian clock disruptions to cancer development.
  • Complex gene regulation and external factors contribute to pathological changes, including cancer.
  • Understanding circadian deregulation aids carcinogenicity research and risk assessment.

Purpose of the Study:

  • To review and systematize knowledge on circadian modulators as chemotherapy agents.
  • To explore the role of REV-ERBs and RORs in cancer.
  • To identify future research directions for circadian-based cancer therapies.

Main Methods:

  • Literature review and synthesis of existing research.
  • Analysis of small-molecule modulators targeting circadian clock nuclear factors (REV-ERBs and RORs).
  • Examination of agonist and inverse agonist activities in cancer contexts.

Main Results:

  • Circadian clock genes are relatively well-characterized, but their regulation is complex.
  • Interplay of genes, expression products, and environmental factors can lead to cancer.
  • Circadian modulators show potential as targeted chemotherapy agents.

Conclusions:

  • Circadian modulators, particularly those affecting REV-ERBs and RORs, represent a promising avenue for novel cancer chemotherapy.
  • Further research is needed to fully elucidate their therapeutic potential and mechanisms in various cancer types.
  • Targeting the circadian clock offers new possibilities for neoplastic cell treatment.

Related Concept Videos

Circadian Rhythms and Gene Regulation02:19

Circadian Rhythms and Gene Regulation

The biological clock is involved in many aspects of regulating complex physiology in all animals. It was in 1935 when German zoologists, Hans Kalmus and Erwin Bünning, discovered the existence of circadian rhythm in Drosophila melanogaster. However, the internal molecular mechanisms behind the circadian clock remained a mystery until 1984, when Jeffrey C. Hall, Michael Rosbash, and Michael W. Young discovered the expression of the Per gene oscillating over a 24-hour cycle. In subsequent years,...
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Circadian Rhythms and Gene Regulation02:19

Circadian Rhythms and Gene Regulation

The biological clock is involved in many aspects of regulating complex physiology in all animals. It was in 1935 when German zoologists, Hans Kalmus and Erwin Bünning, discovered the existence of circadian rhythm in Drosophila melanogaster. However, the internal molecular mechanisms behind the circadian clock remained a mystery until 1984, when Jeffrey C. Hall, Michael Rosbash, and Michael W. Young discovered the expression of the Per gene oscillating over a 24-hour cycle. In subsequent years,...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...